Slowing aortic valve disease with ataciguat
Part of Heart & circulation clinical trials.
This trial tests a new pill, ataciguat, to slow down the progression of moderate calcific aortic valve stenosis (a condition where your aortic valve stiffens). If you have moderate valve narrowing and meet the other criteria, participation could help find a way to delay needing surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older
- You have moderate calcific aortic valve stenosis with specific valve area and calcium scores
- Your heart's pumping ability (ejection fraction) is 45% or better
- You are not planning to have aortic valve surgery in the next 6 months
- You do not have certain other heart valve problems or congenital valve disease
- You do not have certain types of cardiomyopathy or untreated blocked coronary arteries
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with moderate aortic valve disease to learn how their condition changes. It does not test a new treatment but will help doctors better understand the disease.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This trial tests if the drug vericiguat can slow down the buildup of calcium in the aortic valve, which causes it to narrow and stiffen. If you have mild-to-moderate aortic valve stenosis and meet the other criteria, this study may help protect your valve from getting worse.
This study compares a new artificial aortic valve (Myval THV) with standard medical treatment for people with moderate aortic stenosis—a condition where the heart valve doesn't open fully. The trial tests whether the new valve can help improve symptoms and heart function.
This trial tests whether a PCSK9 inhibitor (a cholesterol-lowering medicine) can slow the progression of calcific aortic stenosis, a heart valve condition. It may be an option for people with mild or moderate valve narrowing who are not yet ready for surgery.
This trial tests if a medication called PCSK-9 inhibitor can slow the progression of calcified aortic valve disease, a condition where the heart's aortic valve becomes stiff and narrow. It is for people who also have heart disease or very high cholesterol that hasn't been controlled well with statins.
Hear when a new Moderate Aortic Valve Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.